Pharmacokinetics and pharmacodynamics of colistin

Roger Leigh Nation, Phillip John Bergen, Jian Li

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

The increasing prevalence of multidrug-resistant Gram-negative bacteria worldwide has resulted in colistin, administered as its inactive prodrug colistin methanesulfonate (CMS), being increasingly used as a last-line therapy to treat infections caused by these pathogens. Developed well before contemporary drug development procedures, substantial improvements in the understanding of its chemistry, pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships have occurred over the last decade which have enabled substantial progress towards optimising its clinical use in different patient populations. This has resulted in the first scientifically based dosing algorithm for various categories of critically ill patients receiving CMS to generate a desired target steady-state plasma concentration of formed colistin. It has become clear that monotherapy with CMS is unlikely to generate plasma colistin concentrations that are reliably efficacious. With nephrotoxicity preventing simply increasing the dose of CMS, combination therapy may be required in order to maximise efficacy and minimise the emergence of resistance.
Original languageEnglish
Title of host publicationFundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics
EditorsAlexander A Vinks, Hartmut Derendorf, Johan W Mouton
Place of PublicationNew York NY USA
PublisherSpringer
Pages351 - 380
Number of pages30
ISBN (Print)9780387756127
DOIs
Publication statusPublished - 2014

Cite this

Nation, R. L., Bergen, P. J., & Li, J. (2014). Pharmacokinetics and pharmacodynamics of colistin. In A. A. Vinks, H. Derendorf, & J. W. Mouton (Eds.), Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics (pp. 351 - 380). New York NY USA: Springer. https://doi.org/10.1007/978-0-387-75613-4_14
Nation, Roger Leigh ; Bergen, Phillip John ; Li, Jian. / Pharmacokinetics and pharmacodynamics of colistin. Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. editor / Alexander A Vinks ; Hartmut Derendorf ; Johan W Mouton. New York NY USA : Springer, 2014. pp. 351 - 380
@inbook{837c6f47873b4afa899227ab97710d30,
title = "Pharmacokinetics and pharmacodynamics of colistin",
abstract = "The increasing prevalence of multidrug-resistant Gram-negative bacteria worldwide has resulted in colistin, administered as its inactive prodrug colistin methanesulfonate (CMS), being increasingly used as a last-line therapy to treat infections caused by these pathogens. Developed well before contemporary drug development procedures, substantial improvements in the understanding of its chemistry, pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships have occurred over the last decade which have enabled substantial progress towards optimising its clinical use in different patient populations. This has resulted in the first scientifically based dosing algorithm for various categories of critically ill patients receiving CMS to generate a desired target steady-state plasma concentration of formed colistin. It has become clear that monotherapy with CMS is unlikely to generate plasma colistin concentrations that are reliably efficacious. With nephrotoxicity preventing simply increasing the dose of CMS, combination therapy may be required in order to maximise efficacy and minimise the emergence of resistance.",
author = "Nation, {Roger Leigh} and Bergen, {Phillip John} and Jian Li",
year = "2014",
doi = "10.1007/978-0-387-75613-4_14",
language = "English",
isbn = "9780387756127",
pages = "351 -- 380",
editor = "Vinks, {Alexander A} and Hartmut Derendorf and Mouton, {Johan W}",
booktitle = "Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics",
publisher = "Springer",

}

Nation, RL, Bergen, PJ & Li, J 2014, Pharmacokinetics and pharmacodynamics of colistin. in AA Vinks, H Derendorf & JW Mouton (eds), Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. Springer, New York NY USA, pp. 351 - 380. https://doi.org/10.1007/978-0-387-75613-4_14

Pharmacokinetics and pharmacodynamics of colistin. / Nation, Roger Leigh; Bergen, Phillip John; Li, Jian.

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. ed. / Alexander A Vinks; Hartmut Derendorf; Johan W Mouton. New York NY USA : Springer, 2014. p. 351 - 380.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Pharmacokinetics and pharmacodynamics of colistin

AU - Nation, Roger Leigh

AU - Bergen, Phillip John

AU - Li, Jian

PY - 2014

Y1 - 2014

N2 - The increasing prevalence of multidrug-resistant Gram-negative bacteria worldwide has resulted in colistin, administered as its inactive prodrug colistin methanesulfonate (CMS), being increasingly used as a last-line therapy to treat infections caused by these pathogens. Developed well before contemporary drug development procedures, substantial improvements in the understanding of its chemistry, pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships have occurred over the last decade which have enabled substantial progress towards optimising its clinical use in different patient populations. This has resulted in the first scientifically based dosing algorithm for various categories of critically ill patients receiving CMS to generate a desired target steady-state plasma concentration of formed colistin. It has become clear that monotherapy with CMS is unlikely to generate plasma colistin concentrations that are reliably efficacious. With nephrotoxicity preventing simply increasing the dose of CMS, combination therapy may be required in order to maximise efficacy and minimise the emergence of resistance.

AB - The increasing prevalence of multidrug-resistant Gram-negative bacteria worldwide has resulted in colistin, administered as its inactive prodrug colistin methanesulfonate (CMS), being increasingly used as a last-line therapy to treat infections caused by these pathogens. Developed well before contemporary drug development procedures, substantial improvements in the understanding of its chemistry, pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships have occurred over the last decade which have enabled substantial progress towards optimising its clinical use in different patient populations. This has resulted in the first scientifically based dosing algorithm for various categories of critically ill patients receiving CMS to generate a desired target steady-state plasma concentration of formed colistin. It has become clear that monotherapy with CMS is unlikely to generate plasma colistin concentrations that are reliably efficacious. With nephrotoxicity preventing simply increasing the dose of CMS, combination therapy may be required in order to maximise efficacy and minimise the emergence of resistance.

UR - http://link.springer.com/chapter/10.1007%2F978-0-387-75613-4_14

U2 - 10.1007/978-0-387-75613-4_14

DO - 10.1007/978-0-387-75613-4_14

M3 - Chapter (Book)

SN - 9780387756127

SP - 351

EP - 380

BT - Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

A2 - Vinks, Alexander A

A2 - Derendorf, Hartmut

A2 - Mouton, Johan W

PB - Springer

CY - New York NY USA

ER -

Nation RL, Bergen PJ, Li J. Pharmacokinetics and pharmacodynamics of colistin. In Vinks AA, Derendorf H, Mouton JW, editors, Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics. New York NY USA: Springer. 2014. p. 351 - 380 https://doi.org/10.1007/978-0-387-75613-4_14